Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / ARCT - Arcturus Therapeutics and Primordial Genetics ink exclusive license agreement

ARCT - Arcturus Therapeutics and Primordial Genetics ink exclusive license agreement

Arcturus Therapeutics Ltd.
Arcturus Therapeutics Holdings (ARCT) has been granted an exclusive license of an enzyme for an RNA polymerase (RNApol) by synthetic biology company Primordial Genetics.The enzyme was discovered by Primordial to meet the challenge of manufacturing high-quality, long RNAs for therapeutic applications.Primordial owns proprietary technology relating to RNA manufacturing, specifically its collection of RNA polymerase genes, promoters, and proteins that may be used to synthesize RNA.Arcturus shares up more than 1% premarket.

For further details see:

Arcturus Therapeutics and Primordial Genetics ink exclusive license agreement
Stock Information
Company Name: Arcturus Therapeutics Ltd.
Stock Symbol: ARCT
Market: NASDAQ
Website: arcturusrx.com
Menu
ARCT ARCT Quote ARCT Short ARCT News ARCT Articles ARCT Message Board
Get ARCT Alerts

News, Short Squeeze, Breakout and More Instantly...